Realty Income Corp vs Organon & Co. Common Stock — how do they compare? Realty Income Corp trades at $55.72 (market cap $52.03B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Realty Income Corp is far larger — about 14.4× Organon & Co. Common Stock's market cap, and Realty Income Corp pays the higher dividend (5.92%). Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 128 Days and Organon & Co. Common Stock for 0 Days on average.
| O | OGN | |
|---|---|---|
Market Cap | $52.03B | $3.62B |
Volume | 16,838,213 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $13.81 |
52-Week Low | $53.35 | $5.70 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $82.66B | $11.04B |
Dividend Yield | 5.92% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $55.17, up 0.86% on the day, but remains in a bearish technical trend with recent earnings misses. The REIT maintains strong fundamentals with 92.56% gross margins and consistent dividend payments, though valuation metrics appear elevated with a P/E of 40.14. Recent news highlights the stock's sensitivity to rising Treasury yields, with the 10-year at 5.26% creating headwinds for REIT valuations.
The outlook remains cautious with analyst consensus at Buy (38%) but technical indicators bearish. Key opportunities include the 6% dividend yield and 136 consecutive dividend increases, while risks center on interest rate sensitivity and debt levels approaching 40% of assets. The $64.16 price target suggests 16% upside if fundamentals overcome rate pressures.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →